Latest Advances in Lung Cancer Research

Severe viral infections, such as COVID-19, can increase the risk of lung cancer through immune cell changes, though vaccination significantly reduces these long-term harmful effects.

Dr. Ross Camidge shares clinical insights and personal reflections on the evolution of lung cancer research and the vital importance of innovation in targeted therapies.

Immunotherapy is transforming small cell lung cancer treatment, improving survival in both early and advanced stages, with new drugs offering long-term disease control.

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.

Research develops hypoxic gene expression signatures to predict which muscle-invasive bladder cancer patients will respond to hypoxia-modifying therapies.

A new JAMA review shows that small cell lung cancer, which affects 95% smokers and has only 12-30% five-year survival, is seeing breakthrough improvements with immunotherapy extending survival to 56 months for early-stage disease, though advanced cases remain challenging with most patients relapsing within three months.

Comprehensive review examining molecular mechanisms of cancer invasion and metastasis, identifying potential therapeutic targets for preventing cancer spread.

Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.

Obesity paradox in lung cancer: Study finds obesity associated with improved survival in NSCLC patients, particularly those with preserved skeletal muscle quality and quantity.

Lung cancer mortality trends show significant disparities by sex, age, and ethnicity, with declining rates overall but persistent gaps in healthcare access and outcomes.

Neoadjuvant chemotherapy before surgery significantly improves survival in stage IIIA NSCLC, reducing death risk by 30% and increasing 5-year survival to 41% from 26%.